Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) posted its quarterly earnings data on Tuesday. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.16 by $0.10, FiscalAI reports. The business had revenue of $37.76 million for the quarter, compared to analysts’ expectations of $37.08 million. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%.
Here are the key takeaways from Zevra Therapeutics’ conference call:
- MIPLYFFA sales accelerated: Third-quarter revenue rose 45% year over year to $37.8 million, including $34 million in U.S. MIPLYFFA sales, which increased 12.6% from Q2. The company reported 197 cumulative prescription enrollment forms, 69% payer coverage, and strong refill and retention rates.
- Zevra believes the U.S. NPC market may be larger than its original estimate of 300–350 diagnosed patients, citing a steady flow of newly diagnosed patients and claims-data analysis. It modestly expanded its commercial team and plans to submit an sNDA in the first quarter of 2027 to potentially include patients younger than 24 months.
- The European review of arimoclomol is ongoing, with an expert group and the CHMP expected to evaluate the data; Zevra continues to expect a CHMP opinion in the fourth quarter. The outcome remains a significant regulatory uncertainty for expanding MIPLYFFA access in Europe.
- Zevra ended the quarter with $270.9 million in cash, cash equivalents, and investments, up $10.7 million sequentially, and reported net income of $19.2 million. The company said its balance sheet provides flexibility to expand MIPLYFFA access and advance its pipeline, including the 72-patient celiprolol DiSCOVER trial, which has recorded four confirmed events to date.
Zevra Therapeutics Price Performance
NASDAQ:ZVRA traded up $0.16 on Tuesday, hitting $10.26. 688,233 shares of the company’s stock were exchanged, compared to its average volume of 1,217,035. The firm has a 50-day moving average price of $11.14 and a 200-day moving average price of $10.74. Zevra Therapeutics has a 52 week low of $8.01 and a 52 week high of $15.03. The company has a market cap of $609.28 million, a P/E ratio of 11.15 and a beta of 0.98.
Analysts Set New Price Targets
ZVRA has been the topic of several recent research reports. BTIG Research dropped their price target on Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Monday, July 27th. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a report on Thursday, August 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Zevra Therapeutics in a research report on Wednesday, August 19th. William Blair upgraded Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. Finally, Citizens Jmp upped their price target on Zevra Therapeutics from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Zevra Therapeutics presently has an average rating of “Buy” and a consensus price target of $27.14.
View Our Latest Research Report on Zevra Therapeutics
Insider Activity
In related news, CEO Neil F. Mcfarlane sold 20,000 shares of the company’s stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $11.25, for a total transaction of $225,000.00. Following the sale, the chief executive officer owned 417,225 shares in the company, valued at approximately $4,693,781.25. This represents a 4.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Corey Watton sold 12,300 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $11.25, for a total value of $138,375.00. Following the transaction, the director directly owned 1,800 shares of the company’s stock, valued at $20,250. This trade represents a 87.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.70% of the stock is owned by company insiders.
About Zevra Therapeutics
Zevra Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company combines traditional drug development with data science and patient-focused research to advance therapies for diseases that may have limited treatment options.
Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which is approved in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older, in combination with miglustat.
Read More
- Five stocks we like better than Zevra Therapeutics
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
